Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Nurse Practitioner December 2008 Darlene P. Peters	Colon Cancer Screening: Recommendations and Barriers to Patient Participation Advanced practice nurses and nurse researchers can play a vital role in improving colon cancer screening among patients.
Fast Company July 1, 2007	Going on the Gold Standard What it takes for your company to join the cancer fight.
Managed Care March 2007 Martin Sipkoff	Managing Cancer Treatment Begins Before Diagnosis Health plans are increasingly involved in promoting the lifestyle changes that help their members avoid cancer, and are increasingly involved in clinical trials if prevention fails.
The Motley Fool May 1, 2007 Mike Havrilla	Heads Up, Biotech Investors Big news is in the offing for these companies. Pozen... Progenics... Zymogenetics... etc.
American Family Physician February 1, 2001 Thomas J. Gates	Screening for Cancer: Evaluating the Evidence This article reviews the kind of evidence required to justify screening tests for cancer, with the goal of guiding family physicians through current and future screening controversies...
American Family Physician July 15, 2002 Michael Pignone & Bernard Levin	Recent Developments in Colorectal Cancer Screening and Prevention New information provides further support for efforts to increase the use of colorectal cancer screening and prevention services in adults older than 50 years.
American Family Physician March 15, 2001	Cancer Screening Guidelines Faced with the broad, and sometimes conflicting, range of recommendations for cancer screening, family physicians must determine the most reasonable and up-to-date method of screening...
AskMen.com	Good Health Care News New advice from the American Cancer Society puts a sharper focus on the risks of prostate cancer screening, emphasizing that annual testing can lead to unnecessary biopsies and treatments that do more harm than good.
The Motley Fool July 1, 2011 Luke Timmerman	Dendreon Sways Medicare to Pay for Prostate Cancer Drug The decision by Medicare is no surprise, but it does conclude a period of uncertainty about insurance reimbursement for its lone marketed product.
The Motley Fool June 12, 2007 Brian Lawler	ImClone Tries To Improve Erbitux ImClone is running trials to see if the drug can be used in earlier stages of cancer. Investors shouldn't discount the importance of an approved drug's product label.
The Motley Fool September 14, 2011 Frank Vinluan	Here's How New Roche Cancer Drug Zelboraf Benefits LabCorp A new Roche cancer drug expected to become a blockbuster could also end up being a boon for laboratory and diagnostics firm LabCorp.
The Motley Fool November 18, 2010 Brian Orelli	Worry-Free Dendreon? One step closer to national reimbursement from the Centers for Medicare and Medicaid Services to pay for its prostate cancer treatment Provenge.
American Family Physician December 15, 2002 Randhawa & Fink	Screening for Breast Cancer A case study and question-and-answer group on screening for breast cancer, based on the recommendations of the current U.S. Preventive Services Task Force
Chemistry World September 28, 2012 Andrew Turley	Regorafenib approved in US US authorities have approved Stivarga (regorafenib) tablets for the treatment of advanced colorectal cancer.
American Family Physician July 1, 2002 Bradford J. Wood	Virtual Endoscopy: A Promising New Technology Advanced processing of helical computed tomographic data sets permits three-dimensional and virtual endoscopic models. Such models are noninvasive and require minimal patient preparation, making them ideal for screening.
Pharmaceutical Executive September 1, 2011 Don Creighton	Bridging the Hidden Hurdle in Cancer Cures Diagnostics can boast the efficacy of drug treatments, but delivering the promise depends on a predictable pathway to reimbursement.
Pharmaceutical Executive October 1, 2010	When the Payer IS the Player As Medicare, Medicaid, and the nation's web of private payers gain market power, how can pharma stay ahead of the cost-containment curve?
The Motley Fool September 1, 2010 Brian Orelli	Dendreon: One Step Closer to Worry-Free Back in July, the Centers for Medicare & Medicaid Services announced that it planned on reviewing the reimbursement for Dendreon's prostate cancer treatment Provenge.
Pharmaceutical Executive February 1, 2013 William Looney	Pathways to Progress Cancer is increasingly understood as a collection of rare and mostly treatable conditions rather than the impregnable, monolith portrayed in popular culture. Industry experts review current and pending efforts to turn great science into good practice.
Chemistry World April 21, 2011 David Barden	RNA analysis raises hopes of early cancer diagnosis An improved method for diagnosing colorectal cancer without using invasive techniques has been developed by scientists in China.
Nursing April 2009 Colwell & Gordon	Helping patients combat colon cancer Colorectal cancer is the third most frequently diagnosed cancer in the United States. In 2008, about 148,810 people received this diagnosis and an estimated 49,960 died of the disease.
The Motley Fool February 27, 2004 Alyce Lomax	Genentech's Hope For the past two days, Genentech has been an example of what many investors hinge their hopes and dollars on. Yesterday's FDA approval of the company's groundbreaking cancer drug, Avastin, was the reason positive sentiment remained infectious today.
Pharmaceutical Executive August 1, 2012 Debbie Warner	Adapting to a New Era of Cancer Care Coverage and treatment decisions will be driven by value and defined differently by each stakeholder.
Managed Care January 2005 Sharon Baker	Breast Cancer Screening: Some Plans Do Better Than Others Some of the nation's best health plans are coming up with creative ways to encourage women to get mammograms.
BusinessWeek October 17, 2005 Catherine Arnst	Breast-Cancer Screening: How to Choose Women have varying risk factors for breast cancer and face more test options. Here are some key considerations for making a suitable choice.
Managed Care August 2007 Martin Sipkoff	Soaring Price of Cancer Drugs Leads Plans To New Approaches Insurers are trying different methods, from pay for performance to promoting preventive care, to hold down cost of chemotherapy drugs.
Managed Care January 2008 Peter Kongstvedt	The Managed Care Forecast Here are some of the challenges that health insurers face this year.
Pharmaceutical Executive July 1, 2012 Jill Wechsler	Who Will Pay for New Drugs? Comparative research documenting value and affordability is key to obtaining coverage for high-cost therapies.
Managed Care March 2007	Use of Generics On the Rise Recent data indicate that generic medication accounts for nearly 60% of the drugs dispensed to people in Medicare Prescription Drug Plans and Medicare Advantage plans.
Pharmaceutical Executive February 1, 2013 William Looney	In Cancer, Process Drives Progress Today's most important public health story is the advance in our understanding of the biology of cancer.
Pharmaceutical Executive August 1, 2013 Jill Wechsler	Costs and Coverage Challenge Medicare Drug Plans Rate cuts and fraud concerns create problems for Part D plans and Part B providers.
AskMen.com Jacob Franek	Prostate Cancer Symptoms, Screening & Diagnosis Despite the facts that prostate cancer is the No. 1 cancer occurring in men (aside from skin cancers) and the second leading cause of cancer death (behind lung cancer), many men are still unfamiliar with this highly treatable disease.
Managed Care February 2005	Medicare's Drug Coverage Seeks To Strike Compromise Health plan officials are still trying to determine just how the final rules for the new Medicare prescription drug benefit will affect them, because it appears that government officials tried their best to address the competing concerns of all players.
Managed Care January 2007 Lola Butcher	Employers Publish Guide on Prevention's Worth The National Business Group on Health introduces the Purchaser's Guide to Clinical Preventive Services
BusinessWeek February 16, 2004 Catherine Arnst	Medicare vs. Cancer Patients Refusing to reimburse off-label treatment is far from the best way to cut costs.
Managed Care October 2007	Headlines On Deadline... Health insurance premiums rose an average of 6.1% in 2007... Employers are backing the development of Web-based health records... Commercial health plans posted improvements in 30 of 44 quality of care measures...
Pharmaceutical Executive May 1, 2007 Patrick Clinton	The Topic of Cancer What will tomorrow's cancer commercialization model really look like? We asked four heavyweights from the world of oncology what they thought.
Managed Care May 2001	3rd U.S. Preventive Task Force Issues Recommendations The Third U.S. Preventive Services Task Force released its first of 70 sets of recommendations about the value of specific preventive services...
Managed Care July 2002	Memo Clarifies CMS Guidelines on Injectables Injectable drugs should be covered by Medicare if beneficiaries administer them less than 50 percent of the time, according to a clarification on this issue by the Centers for Medicare and Medicaid services that's set to take effect Aug. 1.
Managed Care November 1999 Arthur L. Baldwin III	Financial and Risk Considerations for Successful Disease Management Programs Results for disease management programs have not been as positive as hoped because of clinical issues, lack of access to capital, and administrative issues....
AskMen.com Jacob Franek	Men's Health Screening Guide Use this men's health screening schedule to stay in top health.
The Motley Fool August 19, 2004 Charly Travers	Myriad's Making Hope Possible This small biotech provides screens that can help catch cancer. Even with solid growth of product revenue, losses could continue to increase as Myriad moves more drugs into clinical development while it transitions into a drug developer.
Chemistry World June 22, 2011 Sarah Houlton	US Approves Cancer Drugs Twice as Fast as Europe Cancer drugs are, on average, approved nearly twice as fast in the US than they are in Europe.
Managed Care June 2002 April Tererri	Health Plans Seem Supportive of Depression-Screening Push The U.S. Preventive Services Task Force made a new recommendation that primary care physicians screen all adult patients for depression
The Motley Fool September 2, 2011 Brian Orelli	Delcath Wants a Do-Over You'd think a drug failing to show an effect would be the worst thing that could happen to a biotech investor, but mixed results are actually much worse.